Limited Offer
Stem Cells and COVID-19
- 1st Edition - April 21, 2022
- Editors: Chandra P. Sharma, Devendra K. Agrawal, Finosh G. Thankam
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 8 9 9 7 2 - 7
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 8 6 2 3 - 9
Stem Cells and COVID-19 presents up-to-date knowledge on the effect of hematopoietic and mesenchymal stem cells to combat SARS-CoV-2 infection in its diagnosis, treatment and preve… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteStem Cells and COVID-19 presents up-to-date knowledge on the effect of hematopoietic and mesenchymal stem cells to combat SARS-CoV-2 infection in its diagnosis, treatment and prevention. In addition, the book critically discusses challenges, highlighting outstanding questions and future perspectives. Written by global experts in the field for both pre-clinical and clinical practitioners, this comprehensive book delves into how stem cells have a strong potential in developing better diagnostic, treatment and preventive strategies in SARS-CoV-2 infection.
Both hematopoietic and mesenchymal stem cells are critical to better understand the response of immune system to coronavirus infection in both healthy and co-morbid conditions in the development of effective vaccines and immunotherapies.
- Focuses on diagnosis, treatment and prevention
- Presents different aspects to enable researchers in the field to move toward designing novel therapeutics in the treatment of COVID-19
- Provides coverage of challenges and future perspectives in this fast-moving field
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- 1: Introduction
- References
- 2: Characteristics and immunobiology of COVID-19
- Abstract
- Introduction
- Structure and etiology
- Pathology of infection
- Immunology and signaling mechanisms
- Cytokine storm
- Current treatment approaches
- Translational avenues and perspectives
- References
- 3: An insight into the molecular mechanisms of mesenchymal stem cells and their translational approaches to combat COVID-19
- Abstract
- Introduction and background
- Pathophysiology of SARS-CoV-2
- Conventional and contemporary translational approaches to combat COVID-19
- Stem cell therapy as a novel translation approach against the COVID-19 pandemic
- Conclusion and outlook for the future
- References
- 4: Inflammatory multisystem syndrome in COVID-19: Insights on off-target organ system in susceptible and recovering population
- Abstract
- Introduction
- Antigen processing and immune responses in COVID-19
- Cytokine storm
- Inflammation in COVID-19
- Respiratory system failure
- Cardiovascular manifestations in COVID-19
- Neurological and renal manifestation of COVID-19
- GI tract manifestations
- Conclusion
- Acknowledgment
- References
- 5: Cytokine storm and stem cell activation in unveiling potential targets for diagnosis and therapy
- Abstract
- Acknowledgments
- Introduction
- Cytokine storms
- Cytokine storms in viral respiratory infections
- Cytokine storms and stem cells
- Conclusion
- References
- 6: Mesenchymal stem cells: Novel avenues in combating COVID-19
- Abstract
- Introduction
- Alveolar cell and SARS-COVID-19
- Cytokine storm
- The reason behind using mesenchymal stem cells
- Conclusion
- References
- 7: Immunomodulatory properties of mesenchymal stem cells and hematopoietic stem cells—Potential therapeutic target for COVID-19
- Abstract
- Acknowledgments
- Introduction
- MSC as a cellular therapy
- Hematopoietic stem cells
- Translational potential of MSCs
- Conclusion
- References
- 8: COVID-19 and acute myocardial injury: Stem cell driven tissue remodeling in COVID-19 infection
- Abstract
- Introduction
- COVID-19: Etiology, transmission, structure, and pathophysiology
- COVID-19-CVD comorbidity
- Stem cells in cardiac remodeling
- ACE2 signaling and cardiac pathology COVID-19 infection
- Stem cell activation and signaling in ACE2 upregulation
- Cytokine surge and stem cell activation in MI
- Sheddases’ response in cardiac stem cell differentiation (major focus to TMPRSS2, CTSL, and ADAM17)
- Perspectives in COVID-19 and cardiac responses
- Translational avenues and future
- References
- 9: Stem cell-driven tissue regeneration as treatment for COVID-19
- Abstract
- Introduction
- Management of COVID-19 by stem cells
- Stem cell activation during pathology
- Growth factors as a vital target
- COVID-19 clinical trials
- Summary and significance
- References
- 10: Stem cell transplantation for COVID-19 management: Translational possibilities and future
- Abstract
- Introduction
- Sources of stem cells
- Use of different types of stem cells in translational research
- Current COVID-19 related clinical trials using stem cells
- Challenges of using stem cells and future perspective
- Conclusion
- References
- 11: Therapeutic scale stem cell-derived exosomes for COVID-19: Models—Validation, management, and strategies
- Abstract
- Introduction to Covid-19
- Pathophysiology
- Interventions
- Stem cell population/product condition addressed outcome
- Exosome for management
- Exosome challenges
- References
- 12: Current strategies and future perspectives in COVID-19 therapy
- Abstract
- Acknowledgments
- Introduction
- COVID-19: An overview
- COVID-19 diagnosis
- Current treatment strategies
- Future perspectives
- Conclusion
- References
- Index
- No. of pages: 248
- Language: English
- Edition: 1
- Published: April 21, 2022
- Imprint: Academic Press
- Paperback ISBN: 9780323899727
- eBook ISBN: 9780323886239
CS
Chandra P. Sharma
Dr. Chandra P. Sharma is a former Adjunct Professor, Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal University, and Hon. Emeritus Professor, College of Biomedical Engineering and Applied Sciences, Purbanchal University, Kathmandu, Nepal. Dr. Sharma is a Solid-State Physicist from IIT Delhi and received his training in biomaterials area in the University of Utah with Prof. D.J. Lyman as a graduate student and in the University of Liverpool, England, with Prof. D.F. Williams as a Post-Doctoral Research Associate. Dr. Sharma has been awarded FBSE (Fellow Biomaterials Science and Engineering) by the International Union of Societies for Biomaterials Science and Engineering (IUS-BSE) in 2008 and FBAO (Fellow Biomaterials and Artificial Organs) by the Society for Biomaterials and Artificial Organs (India) (SBAOI) in 2011 and [17020_LE1] shares Whitaker and National Science Foundation Award—International Society for Artificial Organs (ISAO) USA, invited member ACS (2015–2018).
[17020_LE1]Please check the phrase “and shares Whitaker and National…” for clarity and amend if necessary.
DA
Devendra K. Agrawal
FT